There were 1,595 press releases posted in the last 24 hours and 413,934 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image